Product Information
Ilorasertib is a selective inhibitor of cyclin-dependent kinase 4/6 (CDK4/6) and is being investigated in clinical trials as a potential anticancer agent. Ilorasertib has been shown to inhibit the growth of myelogenous and solid tumours in mouse models. Mechanistic studies have shown that ilarasertib inhibits endothelial cell proliferation by suppressing vascular endothelial growth factor production and inhibits tumor xenografts by blocking mitotic progression at the G2/M phase. Ilorasertib also selectively blocks the activity of CDK4/6, which are important for regulating cellular proliferation, translation, transcription, and protein degradation.